Abstract
This predefined analysis of the European Forsteo Observational Study (EFOS) aimed to describe clinical fracture incidence, back pain, and health-related quality of life (HRQoL) during 18 months of teriparatide treatment and 18 months post-teriparatide in the subgroup of 589 postmenopausal women with osteoporosis aged ≥75 years. Data on clinical fractures, back pain (visual analogue scale, VAS), and HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals and analyzed using logistic regression with repeated measures. A repeated-measures model analyzed changes from baseline in back pain VAS and EQ-VAS. During the 36-month observation period, 87 (14.8 %) women aged ≥75 years sustained a total of 111 new fractures: 37 (33.3 %) vertebral fractures and 74 (66.7 %) nonvertebral fractures. Adjusted odds of fracture was decreased by 80 % in the 30 to <36–month interval compared with the first 6-month interval (P < 0.009). Although the older subgroup had higher back pain scores and poorer HRQoL at baseline than the younger subgroup, both age groups showed significant reductions in back pain and improvements in HRQoL postbaseline. In conclusion, women aged ≥75 years with severe postmenopausal osteoporosis treated with teriparatide in normal clinical practice showed a reduced clinical fracture incidence by 30 months compared with baseline. An improvement in HRQoL and, possibly, an early and significant reduction in back pain were also observed, which lasted for at least 18 months after teriparatide discontinuation when patients were taking other osteoporosis medication. The results should be interpreted in the context of an uncontrolled observational study.
Highlights
JB Walsh has received honoraria for lectures from Servier, Eli Lilly and Company, MSD and Amgen
Women aged C75 years with severe postmenopausal osteoporosis treated with teriparatide in normal clinical practice showed a reduced clinical fracture incidence by 30 months compared with baseline
In a subgroup of elderly women aged C75 years, teriparatide significantly reduced the absolute risk for new vertebral fractures by 9.9 % compared with the calcium and vitamin D–supplemented placebo group over a median duration of treatment of 19 months, similar to that seen in postmenopausal women younger than 75 years [21]
Summary
JB Walsh has received honoraria for lectures from Servier, Eli Lilly and Company, MSD and Amgen. Women aged C75 years with severe postmenopausal osteoporosis treated with teriparatide in normal clinical practice showed a reduced clinical fracture incidence by 30 months compared with baseline. An improvement in HRQoL and, possibly, an early and significant reduction in back pain were observed, which lasted for at least 18 months after teriparatide discontinuation when patients were taking other osteoporosis medication. In a subgroup of elderly women aged C75 years, teriparatide significantly reduced the absolute risk for new vertebral fractures by 9.9 % compared with the calcium and vitamin D–supplemented placebo group over a median duration of treatment of 19 months (relative risk reduction 65 %), similar to that seen in postmenopausal women younger than 75 years [21]. The overall fracture outcomes and back pain over the 36-month follow-up for the total study cohort were reported recently [24]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have